Invited talks and seminars

2023

[22] Yonghyun Lee "Nanomedicines for the treatment of disease" 2023 Korean Tissue Engineering and Regenerative Medicine Society, Nov 11, 2023, Seoul, South Korea. 

[21] Yonghyun Lee "Hyaluronic acid-bilirubin Nanomedicines for Biomedical Applications" Invited seminar at Sungkyunkwan University, Oct 31, 2023, Suwon, South Korea. 

[20] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for biomedical applications”  Invitational Symposium for Pusan National University College of Pharmacy Alumni in Commemoration of the 70th Anniversary of Foundation. May 19, 2023, Busan, South Korea.

[19] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for biomedical applications” 2023 Spring International Convention of The Pharmaceutical Society of Korea Apr 20-21, 2023, Gyeongju, South Korea. 

[18] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for anti-cancer and anti-inflammation therapy” The 2023 Annual Meeting of Korean Association of Immunogists, Apr 13-14, 2023, Gwangju, South Korea. 

[17] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for biomedical applications.”  The 2023 Annual Meeting of the Korean Society for Biomaterials, Mar 31, 2023, Pangyo, South Korea. 

2022

[16] Yonghyun Lee “Current Strategies and Potential Prospects of Nanomedicine-mediated Therapy” The Korean Association for the Study of Intestinal Diseases, May 12--14, 2022, Busan, South Korea. 

2021

[15] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” the 2021 UKC symposium of Korean-American Scientist and Engineers Association (KSEA) Dec 15-18, 2020, Los Angeles, California, USA. 

[14] Yonghyun Lee “Nano-biomedicine platform for anti-cancer and anti-inflammation therapy” Invited Seminar, The Korean Institute of Ocean and Technology, Oct 21, 2021, Busan, South Korea. 

[13] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” The Annual Meeting and International Symposium of The Korean Society of Applied Pharmacology, Oct 15, 2021, Seoul, South Korea. 

[12] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” The Annual Meeting of Korean Tissue Engineering and Regenerative Medicine Society, June 18-19, 2021, Seoul, South Korea. 

2020

[11] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” 2020 International Conference of Korean Society of Pharmaceutical Sciences and Technology, Nov 19-20, 2020, Seoul, South Korea. 

[10] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Pharmaceutical Seminar, College of Pharmacy, Chungbuk National University, Nov 5, 2020, Cheongju, South Korea. 

[9] Yonghyun Lee “Nano-biomedicine platform for anti-cancer and anti-inflammation therapy” Outcome Research Workshops, College of Pharmacy, Ewha Womans Univerisity, Aug 18, 2020, Seoul, South Korea. 

[8] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” Pharmaceutical Seminar, College of Pharmacy, Ewha Womans Univerisity, Apr 02, 2020, Seoul, South Korea. 

2012-2019

[7] Yonghyun Lee and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” 2019 Biomedical Engineering Society Annual Meeting (BMES), Oct 16-19, 2019, Philadelphia, USA.

[6] Yonghyun Lee and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” The 46th Annual Meeting & Exposition of the Controlled Release Society (CRS), Jul 21-24, 2019, Valencia, Spain. 

[5] Yonghyun Lee and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Cancer Hematopoiesis and Immunology Program (CHI Seminar), Rogel Cancer Center, University of Michigan, Mar 1, 2019, Ann Arbor, U.S.A.

[4] Yonghyun Lee and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Pharmaceutical Sciences Seminar, College of Pharmacy, University of Michigan, Dec 5, 2018, Ann Arbor, U.S.A. 

[3] Yonghyun Lee. “Development of new drug candidates using novel approaches” The 1st KAST-KSSEA Young Generation Scientist and Engineers Open Forum. Dec 7-12, 2016, Stockholm, Sweden. 

[2] Yonghyun Lee and Sangyong Jon. “Development of a Histone H1-Specific Aptide as a Novel Apoptotic Imaging Probe and Evaluation for Monitoring Anti-Cancer Drug Responses” 2014 The Korean Society of Molecular Imaging. May 10, 2014, Daegu, South Korea. 

[1] Yonghyun Lee and Yunjin Jun. “Synthesis and evaluation of N-succinylaspart-1-yl celecoxib as a colon specific prodrug of celecoxib.” Symposium on Development and research of original new drug, July 4-6, 2012, Shenyang, China.